Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023
Leanne PM van Leeuwen,Marc C Shamier,Babs E Verstrepen,Hannelore M Götz,Katharina S Schmitz,Najlae Akhiyate,Koen Wijnans,Susanne Bogers,Martin E van Royen,Eric CM van Gorp,Marion PG Koopmans,Rory D de Vries,Corine H GeurtsvanKessel and Luca M Zaeck
DOI: https://doi.org/10.2807/1560-7917.es.2024.29.38.2400575
2024-09-21
Eurosurveillance
Abstract:In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels 1 year post vaccination in at-risk individuals who received two doses of MVA-BN administered subcutaneously with an interval of 4 weeks, without prior smallpox or mpox vaccination. Continuous surveillance is essential to understand the impact of declining antibody levels.
infectious diseases
What problem does this paper attempt to address?